Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
sodium chloride 1 endocrinologydiseasesdrugs
Octreotide 2 endocrinologydiseasesdrugs
carcinoid 2 endocrinologydiseases
neuroendocrine tumor 2 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Octreotide 5302 allowed)Mostly (84%) naïve patients (only SSAs for ≤ 2 weeks allowed, > 6 months previously)Study drug Octreotide LAR 30 intramuscular every 28 daysLanreotide 120 mg deep subcutaneous injection every 28 daysCenters
Octreotide 20512 the role of prophylactic cholecystectomy in metastatic patients facing resection of primary tumors. Octreotide seemed to be responsible for severe toxicity more frequently than lanreotide (45.2% vs. 25.7%, respectively).
sodium chloride 6800 informed of patient's assignment to the treatment or placebo groups. Then, a solution of octreotide or sodium chloride was administered by members of the hospital staff not involved in the trial, but the method for concealment
Select Disease Character Offset Disease Term Instance
carcinoid 17827 analysis of the control arm (placebo + LAR 30) in patients with advanced progressive GEP-NETs with carcinoid syndrome. Focusing on the 41 SSA-naïve cases, median PFS was 13.6 months, similar to the PBO-LAN group
carcinoid 24212 used: (((neuroendocrine OR endocrine) AND (tumor OR tumour OR cancer OR carcinoma OR neoplasm*)) OR carcinoid OR “islet cell carcinoma”) AND (digestive OR gastrointestinal OR gastroenteropancreatic OR pancreatic
neuroendocrine tumor 103 Title: OncotargetAntiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumor s: a systematic review and meta-analysisElettra MerolaFrancesco PanzutoGianfranco Delle Fave1 Department
neuroendocrine tumor 546 antineoplastic efficacy and safety of somatostatin analogs (SSAs) in advanced gastro-entero-pancreatic neuroendocrine tumor s (GEP-NETs). Randomized controlled trials (RCTs) reporting the hazard ratio (HR) for disease progression

You must be authorized to submit a review.